4//SEC Filing
Szyman Catherine M. 4
Accession 0001225208-24-002191
CIK 0001099800other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 5:25 PM ET
Size
14.0 KB
Accession
0001225208-24-002191
Insider Transaction Report
Form 4
Szyman Catherine M
CVP, Critical Care & Vascular
Transactions
- Exercise/Conversion
Common Stock
2024-02-13$36.75/sh+20,000$735,000→ 54,813.571 total - Sale
Common Stock
2024-02-13$86.46/sh−20,000$1,729,200→ 34,813.571 total - Exercise/Conversion
Common Stock
2024-02-15$36.75/sh+27,000$992,250→ 61,813.571 total - Sale
Common Stock
2024-02-15$85.62/sh−27,000$2,311,654→ 34,813.571 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2024-02-13−20,000→ 27,000 totalExercise: $36.75From: 2018-05-11Exp: 2024-05-10→ Common Stock (20,000 underlying) - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2024-02-15−27,000→ 0 totalExercise: $36.75From: 2018-05-11Exp: 2024-05-10→ Common Stock (27,000 underlying)
Footnotes (2)
- [F1]This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeother
Related Parties
1- filerCIK 0001438538
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 5:25 PM ET
- Size
- 14.0 KB